BRPI0817007A2 - Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica - Google Patents
Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêuticaInfo
- Publication number
- BRPI0817007A2 BRPI0817007A2 BRPI0817007A BRPI0817007A2 BR PI0817007 A2 BRPI0817007 A2 BR PI0817007A2 BR PI0817007 A BRPI0817007 A BR PI0817007A BR PI0817007 A2 BRPI0817007 A2 BR PI0817007A2
- Authority
- BR
- Brazil
- Prior art keywords
- stimulating factor
- colony stimulating
- macrophage colony
- granulocyte macrophage
- binding protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99434307P | 2007-09-18 | 2007-09-18 | |
| US8755108P | 2008-08-08 | 2008-08-08 | |
| PCT/US2008/010888 WO2009038760A2 (en) | 2007-09-18 | 2008-09-18 | Human gm-csf antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0817007A2 true BRPI0817007A2 (pt) | 2015-03-24 |
Family
ID=40210593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817007 BRPI0817007A2 (pt) | 2007-09-18 | 2008-09-18 | Proteína de ligação a antígeno isolada, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar a proteína de ligação a antígeno, para tratar ou prevenir uma condição, para inibir a ligação de fator de estimulação de colônia de macrófago granulócito à porção extracelular de receptor de fator de estimulação de colônia de macrófago granulócito, e para inibir atividade de fator de estimulação de colônia de macrófago granulócito, e, composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8268311B2 (pt) |
| EP (2) | EP2236519A1 (pt) |
| JP (1) | JP2010538676A (pt) |
| KR (1) | KR101274356B1 (pt) |
| CN (1) | CN101861336A (pt) |
| AR (1) | AR066164A1 (pt) |
| AU (1) | AU2008302747B2 (pt) |
| BR (1) | BRPI0817007A2 (pt) |
| CA (1) | CA2698667C (pt) |
| CL (1) | CL2008002750A1 (pt) |
| CR (1) | CR11374A (pt) |
| EA (1) | EA201000490A1 (pt) |
| MX (1) | MX2010002968A (pt) |
| NZ (1) | NZ583787A (pt) |
| PE (1) | PE20091193A1 (pt) |
| TW (1) | TW200918553A (pt) |
| WO (1) | WO2009038760A2 (pt) |
| ZA (1) | ZA201002160B (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010527939A (ja) * | 2007-05-23 | 2010-08-19 | シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド | 中和抗体 |
| WO2009062238A1 (en) * | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| US8679502B2 (en) | 2007-11-13 | 2014-03-25 | Evec Inc. | Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same |
| KR101824512B1 (ko) | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
| DK2376121T4 (da) * | 2008-12-22 | 2021-08-16 | Univ Melbourne | Slidgigtbehandling |
| EP3381471B1 (en) | 2008-12-22 | 2024-03-20 | The University of Melbourne | Pain treatment |
| CA2759506A1 (en) * | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
| US20120116059A1 (en) * | 2009-05-05 | 2012-05-10 | Morphosys Ag | Treatment For M Treatment For Multiple Sclerosis |
| AU2011331162B2 (en) * | 2010-11-18 | 2016-07-07 | Merck Serono S.A. | Antibody with specificity for GM-CSF (I) |
| US9567398B2 (en) | 2010-11-18 | 2017-02-14 | Merck Serono S.A. | Antibody with specificity for GM-CSF (II) |
| BR112013033944A2 (pt) | 2011-07-06 | 2017-12-19 | Morphosys Ag | combinação sinérgica |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| CN104995210A (zh) * | 2012-09-20 | 2015-10-21 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| RU2714919C2 (ru) | 2013-08-30 | 2020-02-21 | Такеда Гмбх | Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| US11173208B2 (en) | 2014-05-07 | 2021-11-16 | Takeda Gmbh | Liquid formulation comprising GM-CSF neutralizing compound |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| WO2016048247A1 (en) * | 2014-09-26 | 2016-03-31 | National University Of Singapore | Methods and compositions for modulating th-gm cell function |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016079277A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist in the treatment of an infectious disease |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| CN107531784B (zh) | 2015-04-29 | 2021-08-27 | 生物医学研究所 | 通过多特异性抗体超强力地中和细胞因子和其用途 |
| JP2018527903A (ja) * | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Gdf11結合タンパク質およびその使用 |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| EP3484499A4 (en) * | 2016-07-14 | 2020-05-13 | Scholar Rock, Inc. | TGFB ANTIBODIES, METHODS AND USE |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| DK3328887T3 (da) | 2016-09-19 | 2021-09-20 | I Mab Biopharma Hangzhou Co Ltd | Anti-GM-CSF antistoffer og anvendelser deraf |
| HRP20230308T1 (hr) | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US12624086B2 (en) * | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| AU2019464494A1 (en) * | 2019-09-03 | 2022-04-14 | OncoTab, Inc. | Tumor specific antibody conjugates and uses therefor |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| WO2021202904A1 (en) * | 2020-04-03 | 2021-10-07 | Sorrento Therapeutics, Inc. | Engineered antibodies that bind lags |
| JP2020162622A (ja) * | 2020-06-25 | 2020-10-08 | インスティテュート フォー リサーチ イン バイオメディシン | 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用 |
| EP4259284A4 (en) * | 2020-12-10 | 2026-02-11 | Univ Arizona State | CANINE CANCER VACCINE |
| WO2023200873A2 (en) * | 2022-04-12 | 2023-10-19 | Washington University | Chimeric antigen receptor compositions and methods of using the same |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| CN117126277B (zh) * | 2023-10-26 | 2024-01-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| NZ234479A (en) * | 1989-07-14 | 1992-03-26 | Schering Corp | Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2060741A1 (en) * | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| DK0575319T3 (da) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Kloning og ekspression af Renilla-luciferase |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| JPH06508035A (ja) | 1991-06-14 | 1994-09-14 | ディーエヌエックス コーポレーション | トランスジェニックブタにおけるヒトヘモグロビンの生産 |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| ATE290205T1 (de) | 1996-12-12 | 2005-03-15 | Prolume Ltd | Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU765703B2 (en) | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| ATE444308T1 (de) | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon |
| EP1631315B1 (en) * | 2003-09-24 | 2014-07-30 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| CA2541360A1 (en) * | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| ATE435238T1 (de) * | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| MX2007012569A (es) * | 2005-04-18 | 2007-12-06 | Micromet Ag | Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos. |
| ES2918209T3 (es) * | 2005-05-18 | 2022-07-14 | Morphosys Ag | Anticuerpos anti-GM-CSF y usos a partir de los mismos |
| JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US8609816B2 (en) * | 2005-12-08 | 2013-12-17 | Medarex, L.L.C. | Human monoclonal antibodies to O8E |
| KR101395515B1 (ko) * | 2006-02-08 | 2014-05-14 | 모르포테크, 인크. | 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체 |
| US20080206241A1 (en) | 2006-11-21 | 2008-08-28 | Kalobios Pharmaceuticals Inc. | Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist |
| KR101824512B1 (ko) | 2008-04-28 | 2018-02-02 | 휴머니건, 아이엔씨. | 과립구-대식세포 콜로니 자극 인자에 대한 항체 |
-
2008
- 2008-09-08 TW TW097134377A patent/TW200918553A/zh unknown
- 2008-09-15 CL CL2008002750A patent/CL2008002750A1/es unknown
- 2008-09-17 PE PE2008001620A patent/PE20091193A1/es not_active Application Discontinuation
- 2008-09-18 EP EP10166472A patent/EP2236519A1/en not_active Ceased
- 2008-09-18 AR ARP080104050A patent/AR066164A1/es not_active Application Discontinuation
- 2008-09-18 CA CA2698667A patent/CA2698667C/en not_active Expired - Fee Related
- 2008-09-18 WO PCT/US2008/010888 patent/WO2009038760A2/en not_active Ceased
- 2008-09-18 BR BRPI0817007 patent/BRPI0817007A2/pt not_active IP Right Cessation
- 2008-09-18 CN CN200880116214A patent/CN101861336A/zh active Pending
- 2008-09-18 MX MX2010002968A patent/MX2010002968A/es active IP Right Grant
- 2008-09-18 JP JP2010525835A patent/JP2010538676A/ja active Pending
- 2008-09-18 US US12/675,013 patent/US8268311B2/en active Active
- 2008-09-18 AU AU2008302747A patent/AU2008302747B2/en not_active Ceased
- 2008-09-18 EA EA201000490A patent/EA201000490A1/ru unknown
- 2008-09-18 KR KR1020107008307A patent/KR101274356B1/ko not_active Expired - Fee Related
- 2008-09-18 NZ NZ583787A patent/NZ583787A/en not_active IP Right Cessation
- 2008-09-18 EP EP08832053A patent/EP2205636A2/en not_active Withdrawn
-
2010
- 2010-03-26 ZA ZA2010/02160A patent/ZA201002160B/en unknown
- 2010-04-15 CR CR11374A patent/CR11374A/es unknown
-
2012
- 2012-08-20 US US13/589,935 patent/US8481704B2/en active Active
-
2013
- 2013-06-11 US US13/914,905 patent/US20130259799A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ583787A (en) | 2012-05-25 |
| AU2008302747B2 (en) | 2012-02-02 |
| CN101861336A (zh) | 2010-10-13 |
| TW200918553A (en) | 2009-05-01 |
| CL2008002750A1 (es) | 2009-02-06 |
| AU2008302747A1 (en) | 2009-03-26 |
| WO2009038760A2 (en) | 2009-03-26 |
| PE20091193A1 (es) | 2009-09-06 |
| KR20100059985A (ko) | 2010-06-04 |
| US20130259799A1 (en) | 2013-10-03 |
| JP2010538676A (ja) | 2010-12-16 |
| CA2698667C (en) | 2013-12-24 |
| EP2236519A1 (en) | 2010-10-06 |
| US8481704B2 (en) | 2013-07-09 |
| MX2010002968A (es) | 2010-06-15 |
| US20110189082A1 (en) | 2011-08-04 |
| EA201000490A1 (ru) | 2010-10-29 |
| US8268311B2 (en) | 2012-09-18 |
| AR066164A1 (es) | 2009-07-29 |
| EP2205636A2 (en) | 2010-07-14 |
| US20130071923A1 (en) | 2013-03-21 |
| ZA201002160B (en) | 2011-06-29 |
| CR11374A (es) | 2010-05-19 |
| WO2009038760A3 (en) | 2009-08-20 |
| CA2698667A1 (en) | 2009-03-26 |
| KR101274356B1 (ko) | 2013-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810305A2 (pt) | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" | |
| BRPI0807269A2 (pt) | "anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos" | |
| BRPI0915105A2 (pt) | composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer | |
| BR112013014708A2 (pt) | composto, composição farmacêutica, e, método de inibir ou modular a atividade da cinase de proteína em uma amostra biológica | |
| BRPI0916964A2 (pt) | polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo | |
| HK1203077A1 (en) | Modified nucleoside, nucleotide, and nucleic acid compositions | |
| BR112012024287A2 (pt) | anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira | |
| BRPI0816014A8 (pt) | anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina | |
| BRPI0922106A2 (pt) | anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição | |
| BRPI0813311A2 (pt) | Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica. | |
| BR112013033350A2 (pt) | imunocitocina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
| BRPI0820552A2 (pt) | Polipetídeo isolado, polinucleotídeo isolado, construção de ácido nucléico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir o polipeptídeo, para produzir uma proteína, e para degradar ou converter um material de biomassa, planta, parte vegetal ou célula vegetal transgêncica, método, composição, e. uso do polipeptídio. | |
| EP2126072A4 (en) | MATERIALS AND METHOD FOR THE INDIVIDUAL MOLECULE SEQUENCING OF NUCLEIC ACIDS | |
| BRPI0809661A2 (pt) | Composição farmacêutica estabilizada contendo pregabalina | |
| BRPI0813242A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição. | |
| BRPI0820647A2 (pt) | Polipeptídeo isolado, polinucleotídeo isolado, construção de ácido nucleico, célula hospedeira recombinante, métodos para produzir o polipeptídeo e um mutante de uma célula percursora, célula mutante, planta transgênica, parte de planta ou célula de planta, molécula de rna inibidora de filamento duplo, e, métodos para inibir a expressão de um polipeptídeo um uma célula e para produzir uma proteína e para degradar um xilano | |
| BRPI0913475A2 (pt) | Molécula de ácido nucleico, vetor, célula, método para proteção de uma célula, métodos para expressão de uma proteína de interesse, método para adição ou intensificação da adaptabilidade ou resistência de uma célula e kit | |
| BR112014006158A2 (pt) | molécula de ligação, molécula de ácido nucléico, vetor, célula hospedeira, processo para preparar uma molécula de ligação, métodos para acentuar uma resposta imune em um indivíduo humano, para tratar câncer em um indivíduo humano em necessidade do mesmo, para reduzir o tamanho de um tumor ou inibir o crescimento de células cancerosas em um indivíduo ou reduzir ou inibir o desenvolvimento do câncer metastático em um indivíduo sofrendo de câncer, uso de uma molécula de ligação, e, composição farmacêutica | |
| EP2175016A4 (en) | ANTI-PROMININ-1 ANTIBODY WITH ADCC ACTIVITY OR CDC ACTIVITY | |
| BRPI0816117A2 (pt) | Proteína de ligação de antígeno, anticorpo isolado, anticorpo de neutralização, composição farmacêutica, molécula de ácido nucléico, métodos para fabricar uma proteína de ligação de antígeno, para diminuir o nível de soro de colesterol em um paciente, para tratar ou prevenir uma condição, e, uso de uma proteína de ligação de antígeno. | |
| IL213039A (en) | Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors | |
| BRPI0820068A2 (pt) | Composição para nutrição humana e/ou animal, usos derivados e leveduras | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| BR112012004823A2 (pt) | composto de ligação, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos pra produzir um polipeptídeo e para intensificar uma resposta imune em um sujeiro humano, composição farmacêutica, e, anticorpo ou fragmento de ligação de antígeno | |
| BRPI0906997A2 (pt) | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |